Should I buy or sell G1 Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks .

What is G1 Therapeutics' stock price target for 2024?

4 analysts have issued 1 year price objectives for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $12.00. On average, they expect the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 128.8% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts .

How have GTHX shares performed in 2024?

G1 Therapeutics' stock was trading at $3.05 at the beginning of the year. Since then, GTHX stock has increased by 33.8% and is now trading at $4.08. View the best growth stocks for 2024 here .

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GTHX earnings forecast .

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its earnings results on Wednesday, February, 28th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The company earned $14.87 million during the quarter, compared to the consensus estimate of $12.83 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 106.04% and a negative net margin of 58.13%. During the same quarter last year, the business posted ($0.73) earnings per share.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX) , Sorrento Therapeutics (SRNE) , ImmunoGen (IMGN) , Inovio Pharmaceuticals (INO) , Johnson & Johnson (JNJ) , Gilead Sciences (GILD) , Kadmon (KDMN) , VBI Vaccines (VBIV) , Novavax (NVAX) and Pfizer (PFE) .

When did G1 Therapeutics IPO?

G1 Therapeutics (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free GTHX Stock Alerts

$4.08

-0.23 (-5.34%)

(As of 04/16/2024 ET)

Compare

Today's Range: $4.00
▼
$4.32
50-Day Range: $2.10
▼
$4.88
52-Week Range: $1.08
▼
$5.00

Volume: 568,812 shs
Average Volume: 1.36 million shs
Market Capitalization: $212.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.33

Get G1 Therapeutics alerts:

G1 Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 128.8% Upside
$9.33 Price Target
Short Interest: Bearish
5.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.45
Upright™ Environmental Score
News Sentiment: 1.15
Based on 5 Articles This Week
Insider Trading: Selling Shares
$151,904 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.64) to ($0.26) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.62 out of 5 stars

Medical Sector

259th out of 930 stocks

Pharmaceutical Preparations Industry

106th out of 420 stocks

3.3

Analyst's Opinion

Consensus Rating
G1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
G1 Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.29% of the outstanding shares of G1 Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
G1 Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in G1 Therapeutics has recently increased by 2.60%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
G1 Therapeutics does not currently pay a dividend.
Dividend Growth
G1 Therapeutics does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
G1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for G1 Therapeutics is -2.45.

3.4

News and Social Media Coverage

News Sentiment
G1 Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.
Search Interest
15 people have searched for GTHX on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,904.00 in company stock.
Percentage Held by Insiders
Only 8.23% of the stock of G1 Therapeutics is held by insiders.
Percentage Held by Institutions
Only 24.21% of the stock of G1 Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for G1 Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of G1 Therapeutics is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of G1 Therapeutics is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
G1 Therapeutics has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About G1 Therapeutics Stock (NASDAQ:GTHX)

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GTHX Stock News Headlines

March 21, 2024 | insidertrades.com

G1 Therapeutics, Inc. (NASDAQ:GTHX) CFO Sells $19,771.94 in Stock

April 14, 2024 | americanbankingnews.com

G1 Therapeutics (NASDAQ:GTHX) Given Buy Rating at Needham & Company LLC

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

April 12, 2024 | markets.businessinsider.com

Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal

April 12, 2024 | markets.businessinsider.com

Breaking Down G1 Therapeutics: 5 Analysts Share Their Views

April 7, 2024 | americanbankingnews.com

Head-To-Head Survey: G1 Therapeutics (NASDAQ:GTHX) vs. Galmed Pharmaceuticals (NASDAQ:GLMD)

April 4, 2024 | globenewswire.com

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024 | globenewswire.com

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

March 22, 2024 | marketwatch.com

G1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting Measures

March 22, 2024 | seekingalpha.com

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

March 16, 2024 | finance.yahoo.com

GTHX Apr 2024 3.000 call

March 16, 2024 | finance.yahoo.com

GTHX Apr 2024 3.500 put

March 6, 2024 | finance.yahoo.com

GTHX Mar 2024 3.000 put

March 1, 2024 | globenewswire.com

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | seekingalpha.com

G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Buy Rating Justified by G1 Therapeutics’ Strong Q4 Earnings and Cosela’s Market Traction

February 29, 2024 | finance.yahoo.com

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

February 29, 2024 | finance.yahoo.com

Q4 2023 G1 Therapeutics Inc Earnings Call

February 28, 2024 | investing.com

G1 Therapeutics Inc (GTHX)

February 28, 2024 | finance.yahoo.com

GTHX Jul 2024 2.500 put

February 28, 2024 | msn.com

G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M

February 28, 2024 | markets.businessinsider.com

Forecasting The Future: 5 Analyst Projections For G1 Therapeutics

February 28, 2024 | finance.yahoo.com

G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023

February 28, 2024 | globenewswire.com

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

February 27, 2024 | globenewswire.com

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February 17, 2024 | finance.yahoo.com

G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutions

See More Headlines

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GTHX
CUSIP: N/A
CIK: 1560241
Web: www.g1therapeutics.com
Phone: (919) 213-9835
Fax: 919-741-5830
Employees: 100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.33
High Stock Price Target: $12.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +121.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,970,000.00
Net Margins: -58.13%
Pretax Margin: -54.36%
Return on Equity: -106.04%
Return on Assets: -33.99%

Debt

Debt-to-Equity Ratio: 1.46
Current Ratio: 3.87
Quick Ratio: 3.45

Sales & Book Value

Annual Sales: $82.51 million
Price / Sales: 2.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.68 per share
Price / Book: 6.19

Miscellaneous

Outstanding Shares: 52,200,000
Free Float: 47,903,000
Market Cap: $219.76 million
Optionable: Optionable
Beta: 1.73

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. John E. Bailey Jr. (Age 59)
CEO, President & Director
Comp: $1.06M
Mr. Mark Avagliano (Age 48)
Chief Business Officer
Comp: $628.54k
Mr. John W. Umstead V (Age 39)
Chief Financial Officer
Mr. Terry L. Murdock (Age 64)
Chief Operating Officer
Comp: $541.59k
Mr. William C. Roberts (Age 55)
Vice President of Investor Relations & Corporate Communications
Ms. Monica R. Thomas
General Counsel & Chief Compliance Officer
Mr. Evan Hicks M.B.A.
Vice President of Marketing
Dr. Rajesh K. Malik Ch.B. (Age 65)
M.B., M.D., Chief Medical Officer
Comp: $596.37k
Mr. Andrew Perry (Age 51)
Chief Commercial Officer
Comp: $568.6k
Mr. Jeff Macdonald
Senior Director of Investor Relations & Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GTHX Stock Analysis - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.
What is G1 Therapeutics' stock price target for 2024?: 4 analysts have issued 1 year price objectives for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $12.00. On average, they expect the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 128.8% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.
How have GTHX shares performed in 2024?: G1 Therapeutics' stock was trading at $3.05 at the beginning of the year. Since then, GTHX stock has increased by 33.8% and is now trading at $4.08.
View the best growth stocks for 2024 here.
When is G1 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GTHX earnings forecast.

How were G1 Therapeutics' earnings last quarter?: G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its earnings results on Wednesday, February, 28th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The company earned $14.87 million during the quarter, compared to the consensus estimate of $12.83 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 106.04% and a negative net margin of 58.13%. During the same quarter last year, the business posted ($0.73) earnings per share.
What other stocks do shareholders of G1 Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).
When did G1 Therapeutics IPO?: G1 Therapeutics (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
How do I buy shares of G1 Therapeutics?: Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GTHX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial